Nitrogen-containing bisphosphate drugs used in the treatment of osteoporosis reduce farnesyldiphosphate production and thus prelamin A farnesylation.
Certain nitrogen-containing bisphosphonates used to treat osteoporosis lower farnesyldiphosphate levels, which subsequently impedes the farnesylation of prelamin A.